Let’s Talk: A Conversation with Professor Caicun Zhou
September 17, 2026
Lung cancer care has undergone one of the most dramatic transformations in modern oncology, moving from a landscape defined by limited treatment options and poor prognoses to one shaped by precision biomarker testing, targeted therapy, immunotherapy, and now next-generation bispecific antibodies redefining the standard of care.
In this webcast, Professor Caicun Zhou, Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2 clinical trial for Ivonescimab versus pembrolizumab in NSCLC, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the evolution of lung cancer and China’s growing role in global oncology innovation.
Key topics discussed in this webcast:
- Professor Zhou’s journey from pulmonologist to one of the world’s leading lung cancer oncologists and clinical trial leaders
- The evolution of lung cancer treatment, from chemotherapy to targeted therapies and immunotherapy
- The groundbreaking results from the HARMONi-2 study and the promise of PD-1-VEGF bispecific antibodies, including Ivonescimab
- What is driving China’s rapid rise as a global force in oncology innovation
- Why standardizing biomarker testing globally is essential to advancing precision medicine
CellCarta is excited to share this conversation between lung cancer treatment pioneer Professor Caicun Zhou and our Chief Scientific Business Officer Christopher Ung. We support clinical trials from discovery to translation and companion diagnostic development. If you are working on biomarker driven therapeutics or NSCLC, connect with our team to discover how we can help you accelerate your programs- from targeted genomic assays with rapid turn around times for genomic alterations (AGAs) to custom NGS assay development for your specific program needs.
About the Speakers:
Professor Caicun Zhou
Professor Caicun Zhou is the Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2i clinical trial. He joined the IASLC Board of Directors in 2019 and currently serves as President of the organization, the first from mainland China. With more than 20 years of experience in clinical oncology, Professor Zhou has focused his research on early detection, molecular targeted therapy, anti-angiogenesis therapy, and immunotherapy in lung cancer. Professor Zhou has published over 200 articles in international peer-reviewed journals, including The Lancet Oncology, The Lancet Respiratory Medicine, Journal of Clinical Oncology, and Annals of Oncology, and has authored three books on lung cancer. In 2002, he worked as a visiting scientist at the MD Anderson Cancer Center. He studied medicine at NanTong Medical College, earned his Ph.D. at China Medical University, and served as a fellow at Tokyo National Chest Hospital.
Christopher Ung
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and digital services.
Let’s Talk Webcasts
Our Webcast series features in-depth conversations with thought leaders in precision therapeutics. Join our speakers as they engage in insightful fireside chat-style discussions on a variety of topics in this dynamic space.
Subscribe to our newsletter to not miss our future Webcasts!
Let’s Talk: A Conversation with Professor Caicun Zhou
September 17, 2026
Lung cancer care has undergone one of the most dramatic transformations in modern oncology, moving from a landscape defined by limited treatment options and poor prognoses to one shaped by precision biomarker testing, targeted therapy, immunotherapy, and now next-generation bispecific antibodies redefining the standard of care.
In this webcast, Professor Caicun Zhou, Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2 clinical trial for Ivonescimab versus pembrolizumab in NSCLC, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the evolution of lung cancer and China’s growing role in global oncology innovation.
Key topics discussed in this webcast:
- Professor Zhou’s journey from pulmonologist to one of the world’s leading lung cancer oncologists and clinical trial leaders
- The evolution of lung cancer treatment, from chemotherapy to targeted therapies and immunotherapy
- The groundbreaking results from the HARMONi-2 study and the promise of PD-1-VEGF bispecific antibodies, including Ivonescimab
- What is driving China’s rapid rise as a global force in oncology innovation
- Why standardizing biomarker testing globally is essential to advancing precision medicine
CellCarta is excited to share this conversation between lung cancer treatment pioneer Professor Caicun Zhou and our Chief Scientific Business Officer Christopher Ung. We support clinical trials from discovery to translation and companion diagnostic development. If you are working on biomarker driven therapeutics or NSCLC, connect with our team to discover how we can help you accelerate your programs- from targeted genomic assays with rapid turn around times for genomic alterations (AGAs) to custom NGS assay development for your specific program needs.
About the Speakers:
Professor Caicun Zhou
Professor Caicun Zhou is the Director of Oncology Department at Shanghai East Hospital and Director of Tongji University Cancer Institute, and principle investigator of the HARMONi-2i clinical trial. He joined the IASLC Board of Directors in 2019 and currently serves as President of the organization, the first from mainland China. With more than 20 years of experience in clinical oncology, Professor Zhou has focused his research on early detection, molecular targeted therapy, anti-angiogenesis therapy, and immunotherapy in lung cancer. Professor Zhou has published over 200 articles in international peer-reviewed journals, including The Lancet Oncology, The Lancet Respiratory Medicine, Journal of Clinical Oncology, and Annals of Oncology, and has authored three books on lung cancer. In 2002, he worked as a visiting scientist at the MD Anderson Cancer Center. He studied medicine at NanTong Medical College, earned his Ph.D. at China Medical University, and served as a fellow at Tokyo National Chest Hospital.
Christopher Ung
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and digital services.
Let’s Talk Webcasts
Our Webcast series features in-depth conversations with thought leaders in precision therapeutics. Join our speakers as they engage in insightful fireside chat-style discussions on a variety of topics in this dynamic space.
Subscribe to our newsletter to not miss our future Webcasts!
